Today: The Stokes & Hubbell Capital Management LLC invests in Bristol-Myers Squibb Co. (BMY) Shares

The Stokes & Hubbell Capital Management LLC invests in Bristol-Myers Squibb Co. (BMY) Shares

Stokes & Hubbell Capital Management LLC increased its position in Bristol-Myers Squibb Co. (NYSE:BMY) by 0.0% during the third quarter, Holdings Channel reports. The institutional investor owned 10,239 shares of the biopharmaceutical company’s stock after buying an additional 4 shares during the period. Stokes & Hubbell Capital Management LLC’s holdings in Bristol-Myers Squibb were worth $552,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. WESPAC Advisors SoCal LLC raised its stake in shares of Bristol-Myers Squibb by 5.1% in the second quarter. WESPAC Advisors SoCal LLC now owns 1,538 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 75 shares in the last quarter. Acropolis Investment Management LLC raised its stake in shares of Bristol-Myers Squibb by 21.3% in the third quarter. Acropolis Investment Management LLC now owns 2,815 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 495 shares in the last quarter. Jolley Asset Management LLC raised its stake in shares of Bristol-Myers Squibb by 4.0% in the second quarter. Jolley Asset Management LLC now owns 2,092 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 80 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. bought a new stake in shares of Bristol-Myers Squibb during the second quarter worth approximately $163,000. Finally, Solaris Asset Management LLC raised its stake in shares of Bristol-Myers Squibb by 3.5% in the second quarter. Solaris Asset Management LLC now owns 2,244 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 75 shares in the last quarter. Hedge funds and other institutional investors own 71.28% of the company’s stock.

Bristol-Myers Squibb Co. (NYSE:BMY) traded up 0.41% on Friday, hitting $56.98. 6,228,571 shares of the stock were exchanged. The firm has a market cap of $95.23 billion, a PE ratio of 28.50 and a beta of 0.90. Bristol-Myers Squibb Co. has a 52-week low of $49.03 and a 52-week high of $77.12. The stock’s 50 day moving average price is $52.69 and its 200 day moving average price is $63.10.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.12. The business had revenue of $4.83 billion for the quarter, compared to analyst estimates of $4.76 billion. Bristol-Myers Squibb had a return on equity of 28.98% and a net margin of 18.54%. The firm’s revenue for the quarter was up 21.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.39 earnings per share. Equities research analysts forecast that Bristol-Myers Squibb Co. will post $2.85 earnings per share for the current year.

A number of equities analysts recently issued reports on BMY shares. William Blair reissued a “buy” rating on shares of Bristol-Myers Squibb in a report on Wednesday, August 10th. Citigroup Inc. dropped their price objective on shares of Bristol-Myers Squibb from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Tuesday, August 9th. Argus reissued a “buy” rating and issued a $90.00 price objective on shares of Bristol-Myers Squibb in a report on Saturday, August 13th. Leerink Swann reissued a “buy” rating and issued a $75.00 price objective on shares of Bristol-Myers Squibb in a report on Wednesday, September 7th. Finally, Goldman Sachs Group Inc. reissued a “buy” rating on shares of Bristol-Myers Squibb in a report on Monday, September 12th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the company’s stock. Bristol-Myers Squibb presently has a consensus rating of “Hold” and an average target price of $67.51.

In related news, Director Lamberto Andreotti sold 21,600 shares of the business’s stock in a transaction dated Thursday, September 8th. The stock was sold at an average price of $56.87, for a total transaction of $1,228,392.00. Following the transaction, the director now directly owns 334,499 shares in the company, valued at $19,022,958.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.24% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Related posts

Leave a Comment